Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical development of iproplatin (CHIP).

P J Creaven, L Pendyala, S Madajewicz

    Drugs Under Experimental and Clinical Research
    |January 1, 1986
    PubMed
    Summary

    Iroplatin (CHIP), a novel platinum compound, shows promise in cancer treatment with myelosuppression as its main toxicity. Early studies suggest significant activity in small-cell lung cancer and ovarian carcinoma.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    RT-PCR Quantitation of HSP60 mRNA Expression.

    Methods in molecular medicine·2011
    Same author

    Review of percutaneous therapy for bifurcation lesions in the era of drug-eluting stents.

    Minerva cardioangiologica·2008
    Same author

    Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines.

    Cancer letters·2008
    Same author

    Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival.

    Journal of chemotherapy (Florence, Italy)·2006
    Same author

    S-phase modulation by irinotecan: pilot studies in advanced solid tumors.

    Cancer chemotherapy and pharmacology·2005
    Same author

    A phase I and pharmacokinetic study of BAY59: a novel taxane.

    Oncology·2004

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Iroplatin (CHIP) is a second-generation platinum complex developed for cancer therapy.
    • Preclinical studies indicated minimal nephrotoxicity and myelosuppression as the primary dose-limiting toxicity in animals.

    Purpose of the Study:

    • To review the clinical development of iproplatin (CHIP).
    • To evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in cancer patients.

    Main Methods:

    • Phase I clinical trial assessing dose escalation (20-350 mg/m2) every 3-4 weeks.
    • Pharmacokinetic analysis of platinum-containing species (total Pt, non-protein bound Pt, unchanged iproplatin).
    • Review of early Phase II data for efficacy in specific cancers.

    Main Results:

    • Myelosuppression, particularly thrombocytopenia, was the dose-limiting toxicity in humans.
    • Nausea and vomiting were common but less severe than with cisplatin; nephrotoxicity, neurotoxicity, and ototoxicity were not observed.
    • Pharmacokinetic studies revealed biphasic plasma decay for total platinum (half-life 69.3 h) and monophasic decay for unchanged iproplatin (half-life 1.17 h).
    • Phase II data indicate high activity in small-cell lung cancer and ovarian carcinoma.

    Conclusions:

    • Iroplatin (CHIP) demonstrates a manageable toxicity profile, with myelosuppression as the primary dose-limiting factor.
    • The compound exhibits promising anti-cancer activity, particularly in small-cell lung cancer and ovarian carcinoma.
    • Further clinical development of iproplatin is warranted based on its safety and efficacy data.

    Related Experiment Videos